1
|
D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, Cappuzzo F. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2014; 112:95-102. [PMID: 25349974 PMCID: PMC4453606 DOI: 10.1038/bjc.2014.555] [Citation(s) in RCA: 460] [Impact Index Per Article: 46.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 09/17/2014] [Accepted: 10/02/2014] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether PD-1/PD-L1 are differently expressed in oncogene-addicted NSCLC. METHODS We analysed a cohort of 125 NSCLC patients, including 56 EGFR mutated, 29 KRAS mutated, 10 ALK translocated and 30 EGFR/KRAS/ALK wild type. PD-L1 and PD-1 expression were assessed by immunohistochemistry. All cases with moderate or strong staining (2+/3+) in >5% of tumour cells were considered as positive. RESULTS PD-1 positive (+) was significantly associated with current smoking status (P=0.02) and with the presence of KRAS mutations (P=0.006), whereas PD-L1+ was significantly associated to adenocarcinoma histology (P=0.005) and with presence of EGFR mutations (P=0.001). In patients treated with EGFR tyrosine kinase inhibitors (N=95), sensitivity to gefitinib or erlotinib was higher in PD-L1+ vs PD-L1 negative in terms of the response rate (RR: P=0.01) time to progression (TTP: P<0.0001) and survival (OS: P=0.09), with no difference in PD1+ vs PD-1 negative. In the subset of 54 EGFR mutated patients, TTP was significantly longer in PD-L1+ than in PD-L1 negative (P=0.01). CONCLUSIONS PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies.
Collapse
Affiliation(s)
- A D'Incecco
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - M Andreozzi
- Department of Pathology, Basel Hospital University, Schönbeinstrasse 40, 4003 Basel, Switzerland
| | - V Ludovini
- Division of Medical Oncology, Santa Maria della Misericordia Hospital, Località S. Andrea delle Fratte 1, 06134 Perugia, Italy
| | - E Rossi
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - A Capodanno
- Azienda Ospedaliero-Universitaria Pisana, University Hospital, via Roma 57, 56126 Pisa, Italy
| | - L Landi
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - C Tibaldi
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - G Minuti
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - J Salvini
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - E Coppi
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - A Chella
- Azienda Ospedaliero-Universitaria Pisana, University Hospital, via Roma 57, 56126 Pisa, Italy
| | - G Fontanini
- Department of Surgical, Medical, Molecular Pathology and Critical Area, Pisa University, via Roma 57, 56126 Pisa, Italy
| | - M E Filice
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - L Tornillo
- Department of Pathology, Basel Hospital University, Schönbeinstrasse 40, 4003 Basel, Switzerland
| | - R M Incensati
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - S Sani
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| | - L Crinò
- Division of Medical Oncology, Santa Maria della Misericordia Hospital, Località S. Andrea delle Fratte 1, 06134 Perugia, Italy
| | - L Terracciano
- Department of Pathology, Basel Hospital University, Schönbeinstrasse 40, 4003 Basel, Switzerland
| | - F Cappuzzo
- Department of Medical Oncology, Istituto Toscano Tumori, Civil Hospital, Viale Alfieri 36, 57124 Livorno, Italy
| |
Collapse
|
2
|
Cappuzzo F, Sacconi A, Landi L, Biagioni F, Ludovini V, Sensi E, Salvini J, Fontanini G, Blandino G, Crinò L. MIR-99A/LET7C/MIR-125B Signature to Predict Sensitivity to Anti-Egfr Monoclonal AntiBodies in Metastatic Colorectal Cancer (MCRC). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33142-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|